On June 17, 2020 Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, reported that it will present on Tuesday, June 23, 2020 at the BMO Prescriptions for Success Healthcare Conference (Press release, Mallinckrodt, JUN 17, 2020, View Source [SID1234561201]). Mark Trudeau, President and Chief Executive Officer, and Bryan Reasons, Executive Vice President and Chief Financial Officer, will represent the company in a fireside chat at 8:00 a.m. Eastern Time. To access the webcast, please refer to the webcast link posted on our site at: http://www.mallinckrodt.com/investors. A replay of the fireside chat will also be available following the meeting.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On June 17, 2020 Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) reported that Dean Schorno, the company’s chief financial officer, reported that to present a company overview at the BMO 2020 Prescriptions for Success Healthcare Virtual Conference on Tuesday, June 23, 2020 at 10:30 a.m. Eastern Time (Press release, Rigel, JUN 17, 2020, View Source [SID1234561200]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To access the live and subsequently archived webcast, go to the Investor Relations section of the company’s website at www.rigel.com. Please connect to Rigel’s website several minutes prior to the start of the live webcast to ensure adequate time for any software download that may be necessary.

On June 17, 2020 Kangpu Biopharmaceuticals, a clinical-stage company focused on the discovery and development of next-generation of immunomodulatory small molecules for the treatments of solid tumors, hematological malignancies, auto-immune diseases as well as inflammatory disorders, reported that two posters highlighting preclinical data of the company’s lead drug candidates, KPG-121 and KPG-818, will be presented at the 2020 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Virtual Annual Meeting II to be held from June 22-24, 2020 (Press release, Kangpu Biopharmaceuticals, JUN 17, 2020, View Source [SID1234561199]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the e-poster presentations on June 22-24 are as follows:

Abstract Title: KPG-121, A Novel Cereblon Modulator, Potently Inhibits Growth of Metastatic Castration Resistant Prostate Cancer in Combination with Androgen Receptor Inhibitors Both In Vitro and In Vivo
Abstract Number: 5300
Poster Number: 5327
Poster Session: Novel Antitumor Agents 2

KPG-121 is a novel modulator of the Cerebron (CRBN) E3 ubiquitin ligase complex CRL4CRBN targeting rapid ubiquitination and degradation of casein kinase 1A1 (CK1α) and transcription factors Aiolos and Ikaros. KPG-121 promotes anti-proliferation and anti-angiogenesis activities and enhances immunomodulatory properties. KPG-121 significantly improves anti-tumor efficacies when combined with androgen-receptor antagonists including Enzalutamide, Abiraterone Acetate, Apalutamide, or Darolutamide in xenograft models when compared to the androgen-receptor antagonist therapy alone. KPG-121 is currently being evaluated in a Phase I study in the US for the treatment of patients with metastatic and non-metastatic castration-resistant prostate cancer in combination with Enzalutamide, Abiraterone Acetate, or Apalutamide (NCT03569280 at www.clinicaltrials.gov).

Abstract Title: KPG-818, A Novel Cereblon Modulator, Inhibits Hematological Malignancies in Preclinical Models
Abstract Number: 5671
Poster Number: 6367
Poster Session: Novel Antitumor Agents 3

KPG-818 represents a novel generation of small molecule modulators of the CRBN E3 ubiquitin ligase complex CRL4CRBN and potently induces the ubiquitination and degradation of Aiolos (IKZF3) and Ikaros (IKZF1), two members of the Ikaros family of zinc-finger transcription factors critical in B-cell development. In preclinical studies, KPG-818 demonstrates outstanding in vitro anti-inflammatory properties and broad spectrum of anti-proliferative activities as well as remarkable in vivo efficacy in animal models of multiple blood cancers. KPG-818 is currently being developed in a Phase I study for the treatment of patients with hematological malignancies in the US (NCT04283097 at www.clinicaltrials.gov).

Abstracts and full session details can be found at www.aacr.org.

On June 17, 2020 RemeGen, Co., Ltd. reported positive results from its Phase II study of RC48 (disitamab vedotin) for the treatment of HER2-expressing advanced or metastatic gastric cancer in heavily treated patients at the ASCO (Free ASCO Whitepaper)20 Virtual Scientific Program organized by the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper), which was held on May 29-31, 2020 (Press release, RemeGen, JUN 17, 2020, View Source [SID1234561198]). RC48 (disitamab vedotin) is a novel humanized anti-HER2 antibody drug conjugate (ADC) developed to treat several cancer diseases.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"For the third year in a row, we are pleased to showcase clinical progress of RC48 in a broad range of solid tumor treatments at ASCO (Free ASCO Whitepaper)," said Jianmin Fang, Ph.D., founder and CEO of RemeGen Co., Ltd., "We are encouraged to see positive data from the latest research, and we believe that RC48 has the potential to redefine treatment for patients with HER2-expressing advanced or metastatic gastric cancer."

The single-arm Phase II multicenter clinical study conducted in China was designed to evaluate the efficacy and safety of RC48. The study enrolled 127 patients (IHC2+ including FISH+ and FISH-, and IHC3+) with advanced or metastatic gastric cancer including gastric or gastroesophageal junction adenocarcinoma. The key endpoint of the study was the objective response rate (ORR) of the main efficacy index evaluated by the independent efficacy evaluation committee (IRC). The confirmed ORR was 23.6%, with a median progression free survival period (mPFS) of 4.1 months. The median overall survival time (mOS) was 7.5 months.

All patients evaluated in the study had received 2 or more lines of chemotherapy treatments with a subgroup of patients having received an additional line of systemic therapy treatment such as Herceptin. The study also included patients with low expressing HER2 (IHC2+ / FISH-) tumor, potentially widening the population of patients who may benefit from this therapy. The results of the study demonstrate RC48’s potential in addressing the urgent unmet medical need for this heavily treated patient population.

More information around these findings are found in the virtual scientific program of the ASCO (Free ASCO Whitepaper) Annual Meeting (Abstract #4560).

About RC48
RC48 was developed to treat HER2 expressing solid tumors. It has a novel antibody with a higher affinity to HER2 compared to standard of care, and superior anti-tumor activity compared to other treatments in animal models. RC48 was the first ADC drug approved for human clinical trials in China and favorable safety profile has been observed in clinical trials. It is currently being studied in multiple late-stage clinical trials across solid tumor types.

On June 17, 2020 Centene Corporation (NYSE: CNC) reported that it has been notified of an unsolicited "mini-tender" offer by TRC Capital Investment Corporation ("TRC Capital") to purchase up to 2,000,000 shares of Centene’s common stock at an offer price of $59.00 net per share in cash, which is an approximate 4.75% discount to the $61.94 per share closing price of Centene’s common stock on the New York Stock Exchange on June 12, 2020, the last trading day before the commencement of TRC Capital’s mini-tender offer, and an approximately 7.13% discount to the $63.53 per share closing price of Centene’s common stock on June 17, 2020, the day of this release (Press release, Centene , JUN 17, 2020, https://www.prnewswire.com/news-releases/centene-recommends-stockholders-reject-mini-tender-offer-by-trc-capital-investment-corporation-301079145.html [SID1234561197]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Centene does not endorse TRC Capital’s mini-tender offer and is not associated in any way with TRC Capital, its mini-tender offer or its mini-tender offer documents.

Centene recommends that its stockholders reject the offer and not tender their shares in response to TRC Capital’s below-market offer. This mini-tender offer is at a price below the market price for Centene’s common stock (as of today’s close) and is subject to a number of conditions, including, among others, that there has not been a decrease in the market price of shares of Centene common stock and TRC Capital’s ability to obtain debt financing sufficient, together with cash on hand, to consummate the offer.

TRC Capital has made similar mini-tender offers for the shares of other companies. TRC Capital’s mini-tender offer seeks less than 5% of Centene’s outstanding common stock, thereby avoiding many disclosure requirements and procedural protections of the Securities and Exchange Commission ("SEC"). The SEC has cautioned investors about mini-tender offers in an investor alert, advising that some bidders make mini-tender offers at below-market prices "hoping that they will catch investors off guard if the investors do not compare the offer price to the current market price." The SEC’s cautionary alert for investors regarding mini-tender offers is on its website at: View Source

Stockholders should obtain current market quotations for their shares of Centene common stock, consult with their broker or financial advisor, and exercise caution with respect to TRC Capital’s mini-tender offer. Stockholders who have already tendered shares are advised that they may withdraw their shares by providing the written notice described in the TRC Capital mini-tender offer documents prior to the expiration of the offer, currently scheduled for 12:01 a.m., New York City time, on Wednesday, July 15, 2020.

Centene encourages brokers and dealers, as well as other market participants, to review the SEC’s letter regarding broker-dealer mini-tender offer dissemination and disclosure at View Source

Centene requests that a copy of this press release be included with all distributions of materials relating to TRC Capital’s mini-tender offer for Centene common stock.